Effects of Sacubitril Valsartan sodium combined with Metoprolol tartrate tablets in treatment of patients with coronary heart disease and chronic heart failure
Objective:To observe effects of Sacubitril Valsartan sodium combined with Metoprolol tartrate tablets in treatment of patients with coronary heart disease and chronic heart failure (CHF). Methods:A prospective study was conducted on 60 patients with coronary heart disease and CHF admitted to the hospital from January 2022 to January 2024. According to the random number table method,they were divided into observation group and control group,30 cases in each group. The control group was treated with Metoprolol tartrate,while the observation group was treated with Sacubitril Valsartan sodium on the basis of that of the control group. The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction (LVEF),left ventricular end-diastolic volume (LVEDV),left ventricular end-diastolic diameter (LVEDD),left ventricular end-systolic diameter (LVESD),left ventricular end-systolic volume (LVESV)],disease-related indexes[endothelin-1 (ET-1),nitric oxide (NO),N-terminal B-type brain natriuretic peptide precursor (NT-proBNP) and inflammatory factors[interleukin-6 (IL-6),interleukin-8 (IL-8),high sensitivity C-reactive protein (hs-CRP)],and the incidence of adverse reactions were compared between the two groups before and after the treatment. Results:The total effective rate of the observation group was 93.33％ (28/30),which was higher than 73.33％ (22/30) of the control group,and the difference was statistically significant (P<0.05). After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of LVEDD,LVESD,LVEDV and LVESV in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant (P<0.05). After the treatment,the levels of ET-1 and NT-proBNP in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the NO levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant (P<0.05). After the treatment,the levels of IL-6,IL-8 and hs-CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.05). During the treatment,no obvious adverse reactions occurred in the two groups. Conclusions:Sacubitril Valsartan sodium combined with Metoprolol tartrate in the treatment of the patients with coronary heart disease and CHF can improve the total effective rate of treatment,improve the levels of cardiac function indexes and disease-related indexes,and reduce the levels of inflammatory factors. Moreover,it is superior to simple Metoprolol tartrate treatment.
万方数据
维普
